IQ MPS
IQ Microphysiological Systems Affiliate
An Affiliate of the International Consortium for Innovation and Quality in Drug Development
Leveraging MPS Data for in-Silico Modeling
With new approach methodologies (NAM) evolving in tandem and at a rapid pace, there is an opportunity to integrate them in ways previously thought impossible. This session aims to initiate discussion on how the diverse and complex datasets derived from CIVM and MPS models may be analyzed using quantitative systems biology (QSP), machine learning, and in silico modeling approaches. Examples will be provided through case studies, and a realistic view of the current gaps as well as future outlooks and opportunities will be discussed.
Date & Time
Thursday, September 21, 2023 at 10:00 AM ET
Duration
90 minutes
Agenda
Welcome and Introduction
David Stresser, AbbVie
PBPK as essential tools for MPS integration in Drug Development
Diane Ramsden, AstraZeneca
Advancing Drug Development with MPS-PBPK Integration
Maarten Huisman, UCB Pharma
Q&A
David Stresser, AbbVie
Quantitative translation of MPS toxicity into Clinical Adverse Effects
Carmen Pin, AstraZeneca
Q&A
Diane Ramsden, AstraZeneca
Moderators and Presenters
Diane Ramsden
Director, Oncology DMPK
AstraZeneca
Diane Ramsden is a Director of Oncology DMPK leading the ADME and BA team within AstraZeneca’s Boston site. Her team is evaluating MPS and CIVM models as tools for providing mechanistic ADME insights into small and large molecule disposition.
David Stresser, PhD
Research Fellow
AbbVie
David Stresser is a Senior Principal Research Scientist in the DMPK-BA department at AbbVie and leads a team of ADME scientists focusing on investigations of small molecule clearance, plasma protein binding and drug-drug interactions using conventional and complex in vitro models. He is an active participant in various pharma consortia including the IQ Microphysiological Systems Affiliate.
Maarten Huisman
Director, Quantitative Pharmacology and DMPK
UCB Pharma
Maarten Huisman is a seasoned translational scientist with a Ph.D. in Pharmaceutical Sciences from Utrecht University and a MSc in Biology: Molecular and Medical Genetics from the University of Groningen. He currently serves as the DMPK Lead at UCB, focusing on the discovery and development of novel protein degraders, ASO-conjugates, and antibodies.
Before UCB, Maarten held various roles at 3D-PharmXchange, Oystershell Laboratories (Medical Devices), and 2 Bridge CVBA, and contributed significantly at The Janssen Pharmaceutical Companies of Johnson & Johnson. He's adept in strategic planning, project leadership, and embracing new technologies for drug development. His expertise spans several therapeutic areas including oncology, dermatology, immunology, diabetes, and CNS.
Carmen Pin
Senior Director
AstraZeneca
Dr. Carmen Pin is a modeler at AstraZeneca (Cambridge, UK). Prior to joining AstraZeneca, she led the Computational Gastrointestinal Biology Group at the Quadram IB (Norwich, UK). She has co-authored numerous scientific articles and led several substantial scientific research projects.
